For research use only. Not for therapeutic Use.
LCS3 is a reversible and uncompetitive glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) inhibitor (IC50=3.3 µM and 3.8 µM, respectively). LCS3 shows anti-tumor activity, and induces apoptosis. LCS3 can be used in lung adenocarcinoma (LUAD) research[1].
LCS3 (5 nM-10 µM; 96 h) inhibits lung cancer cell lines, but not non-transformed lung cells[1].
LCS3 (3 µM; 3, 6, and 12 h) induces ROS and NRF2 pathway activation in sensitive lung adenocarcinoma (LUAD) cells[1].
LCS3 (3 µM; 96 h) selectively kills lung adenocarcinoma (LUAD) cell lines, in part through the induction of apoptosis[1].
| Catalog Number | I043380 |
| CAS Number | 109844-92-0 |
| Synonyms | N-(4-chlorophenyl)-5-nitrofuran-2-carboxamide |
| Molecular Formula | C11H7ClN2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C11H7ClN2O4/c12-7-1-3-8(4-2-7)13-11(15)9-5-6-10(18-9)14(16)17/h1-6H,(H,13,15) |
| InChIKey | JDBZJNUHQINERI-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1NC(=O)C2=CC=C(O2)[N+](=O)[O-])Cl |
| Reference | [1]. Fraser D Johnson, et al. Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells. Cell Rep. 2022 Feb 8;38(6):110343. |
